You can buy Oysiendx at the lowest price in the online pharmacy Nextgen.ooo . Osimertinib is an oral drug, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumor EGFR expression is positive for the T790M mutation and which has progressed after first-generation EGFR tyrosine kinase inhibitor therapy. Approximately 10% of patients with NSCLC experience a rapid and clinically effective response to EGFR-TKI due to the presence of specific activating EGFR mutations in tumor cells (deletions in exon 19 and point mutations L858R in exon 21 correlate with response to therapy).
 
The development of third-generation EGFR-TKIs such as osimertinib was a response to changing patterns of tumor resistance after treatment and toxic side effects that impact patients’ quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) was associated with the development of resistance due to activating mutations in the EGFR gene. Then, second-generation EGFR-TKIs (afatinib and dacomitinib) were developed as more potent inhibitors, although their use is associated with increased toxicity due to non-specific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the T790M mutation, which increases EGFR ATP binding activity and leads to poor prognosis for advanced disease. Osimertinib is indicated for the treatment of patients with EGFR-mutated metastatic or locally advanced non-small cell lung tumor as first-line therapy or in case of progression during or after therapy with other first- or second-generation EGFR inhibitors.